Demand Increase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

hi, everyone, thanks for joining me. i'm amara walker in today for fredricka whitfield. and we begin this hour with mass d demonstrations nationwide calling for tighter gun laws. more than 300 rallies happening today. some like the event in d.c. underway right now. that is david hogg, he is one of the co-founders of this rally march for our lives and also a survivor of a mass shooting that happened at marjory stoneman douglas high school in parkland, florida. this is renewing calls to lawmakers to address the gun violence epidemic after a series of horrific mass shootings. moments ag...

Eli Lilly’s popular weight loss drugs have "limited availability" through the end of April

The newest weight loss drug on the market is facing a shortage of supply, according to the U.S. Food and Drug Administration. The FDA approved Zepbound in November as a weight loss management treatment for people with obesity, or those who are overweight with at least one related underlying condition, such as high blood pressure. As a diabetes drug, Zepbound is sold under the brand name Mounjaro, as the two medications contain the same active ingredient, tirzepatide.

Insightful Analysis of TransDigm Group Inc's Latest Financials and Strategic Position

Japan's Advantest said on Wednesday it sees growing demand for its chip testing equipment for memory used for artificial intelligence tasks while reporting a drag from weak electronics sales. Advantest said it sees sales of memory testers reaching 244 billion yen ($1.65 billion) in the financial year ending March, an increase of 5 billion yen from its October outlook but down a quarter on the same period a year earlier. "In order to fulfil all the demand increase in the market we need to make further efforts," Advantest CEO Yoshiaki Yoshida told an earnings briefing.